No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MAIA MAIA Biotechnology
- 3.640
- +0.210+6.12%
Close Jul 19 16:00 ET
- 3.750
- +0.110+3.02%
Post 19:59 ET
79.49MMarket Cap-2318P/E (TTM)
3.750High3.431Low65.88KVolume3.450Open3.430Pre Close235.98KTurnover0.38%Turnover RatioLossP/E (Static)21.84MShares5.99052wk High-13.79P/B63.38MFloat Cap0.82052wk Low--Dividend TTM17.41MShs Float9.640Historical High--Div YieldTTM9.31%Amplitude0.820Historical Low3.582Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
NYSE American Net Change Percentage Gainers & Losers
GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares.
Express News | MAIA Biotechnology Announces Validation Of Clinical And Regulatory Pathways For Telomere-Targeting Cancer Therapies Following FDA Approval Of Geron's Imetelstat
Express News | Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable by Fda’s Approval of a Telomerase Inhibitor Agent Therapy
Express News | Maia Biotechnology Inc- Engaged in Research and Development for a Portfolio of Second-Generation Thio-Like Compounds.
Express News | Maia Biotechnology Inc - Maia's Phase 2 Thio-101 Clinical Trial Is Expected to Near Completion in 2024
Comments
$MAIA Biotechnology(MAIA.US$ Maia Biotechnology Inc - Maia's Phase 2 Thio-101 Clinical Trial Is Expected to Near Completion in 2024
$MAIA Biotechnology(MAIA.US$ Check that uptrend since the PP i posted the PR on March 12! Lovely just lovely! Hehehe![]()
2
$MAIA Biotechnology(MAIA.US$ Maia Biotechnology Inc - Anticipate Full Efficacy Data From Thio-101 in Second Half of This Year
2
1
$MAIA Biotechnology(MAIA.US$ MAIA Biotechnology Reveals New Clinical Data Showing THIO's Strong Efficacy in Non-Small Cell Lung Cancer
1 MINUTE AGO, 8:41 AM EDT
VIA BUSINESSWIRE
1 MINUTE AGO, 8:41 AM EDT
VIA BUSINESSWIRE
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg